Application of inhibitor JAK1 and JAK2 ruxolitinib as pre- and posttransplant therapy in patients with myelofibrosis

Application of inhibitor JAK1 and JAK2 ruxolitinib as pre- and posttransplant therapy in patients with myelofibrosis

Primary myelofibrosis (PMF) is а chronic BCRABL–negative myeloproliferative disorder with progressive clinical course. Allogeneic stem cell transplantation is the only treatment optionin patients with PMF with curative potential. Most of PMF patients have active disease phase at the moment of alloHS...

Full description

Bibliographic Details
Main Authors: M. V. Barabanshchikova, E. V. Morozova, Yu. Yu. Vlasova, V. V. Baykov, L. S. Zubarovskaya, B. V. Afanasyev
Format: Article
Language:Russian
Published: Academician I.P. Pavlov First St. Petersburg State Medical University 2016-03-01
Series:Учёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова
Subjects:
myelofibrosis
januskinase inhibitor
ruxolitinib
allo-hsct
Online Access:https://www.sci-notes.ru/jour/article/view/178

Similar Items

Similar Items